46 results on '"Richman, Lee P."'
Search Results
2. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
3. NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT
4. Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis
5. Tumor cell-intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)
6. Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature
7. Data from Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
8. Supplementary Figure 2 from Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
9. Supplementary Figure 1 from Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
10. Supplementary Methods from Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
11. Supplementary Figure 3 from Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
12. Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis
13. CCR5-edited [CD4.sup.+] T cells augment HIV-specific immunity to enable post-rebound control of HIV replication
14. Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment
15. Human treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression
16. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication
17. Abstract PR11: Tumor cell-intrinsic factors underlie the heterogeneity of immune infiltration and response to immunotherapy in pancreatic cancer
18. Abstract PR14: Emergence of quality metrics for neoantigens: Dissimilarity to the self-proteome as a novel determinant of immunogenicity
19. Abstract B04: Identification of T-cell receptors targeting mutant KRAS in pancreatic cancer
20. Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade
21. Pharmacodynamic monitoring predicts outcomes of CCR5 blockade as GVHD prophylaxis
22. 96 - Extended Course of Maraviroc, a CCR5 Antagonist, Is Safe and Effective in Graft-Versus-Host Disease Prophylaxis. Final Results of a Phase II Study
23. Teenagers, Alcohol and Education: An Annotated Bibliography of Journal Articles
24. Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
25. Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
26. Extended Course of Maraviroc, a CCR5 Antagonist, Is Safe and Effective in Graft-Versus-Host Disease Prophylaxis. Final Results of a Phase II Study
27. Cancer Immunology Miniatures: Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma
28. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
29. Immunologic Effects of CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis
30. Abstract CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma
31. High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning
32. Toll-like receptor 9 and interferon-γ receptor signaling suppress the B-cell fate of uncommitted progenitors in mice
33. Pharamacodynamic Assessment Shows That CCR5 Surface Expression May Serve As an Indicator for Effective CCR5 Blockade in Allogeneic Stem Cell Transplant (alloSCT) Recipients Treated with Maraviroc
34. A Survival Benefit for Reduced Intensity Allogeneic Transplants from Young Unrelated Donors Compared to Older Sibling Donors Depends on the Graft CD8 T-Cell Content
35. Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study
36. CD8 Cell Dose in Peripheral Blood Stem-Cell Grafts Correlates with Relapse and Survival after Reduced Intensity Allogeneic Stem-Cell Transplantation
37. Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma
38. Vitamin D Deficiency Predicts Acute Cutaneous Graft-Versus-Host Disease in Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation
39. Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
40. NKG2D expression by CD8+T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT
41. Distinct H-2-linked Irgenes control both antibody and T cell responses to different determinants on the same antigen, myoglobin*
42. Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature
43. Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma.
44. Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
45. NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.
46. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.